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Infection of primary cultures of human immature monocyte-derived dendritic cells (moDC) with the paramyxovirus Simian Virus 5 (SV5)
results in extensive cytopathic effect (CPE) and induction of apoptosis, but DC maturation pathways are not activated. In this study, we
investigated the relationship between SV5-induced apoptosis and the lack of DC maturation. Reducing CPE and apoptosis in SV5-infected
immature DC by the addition of a pancaspase inhibitor resulted in only low level expression of maturation markers CD40, CD80 and CD86,
suggesting that SV5 infection either actively blocked maturation pathways or failed to provide sufficient signals to activate maturation. To
distinguish between these hypotheses, SV5-infected immature DC were challenged with agonists that stimulate toll-like receptors (TLRs).
Treatment with the TLR-4 agonist LPS or TLR-6 agonist FSL1 enhanced cell surface expression of CD40, CD80 and CD86 on SV5-infected cells
to levels approaching that of mock-infected TLR-treated moDC, but treatment with agonists for TLR-2, -3, -5 or -8 had little effect. Addition of
TLR-4 or -6 agonists to SV5-infected DC also dramatically reduced CPE and apoptosis, but the levels of viral protein and virus yield were not
affected. Similarly, SV5-infected immature moDC were matured by treatment with IL-1β, and these mature infected cells also showed reduced
CPE and apoptosis. In the presence of NFkB inhibitors, TLR-4 and -6 agonists did not promote maturation or reduce apoptosis of SV5-infected
DC, indicating that maturation and cell survival were both dependent on signaling through NFkB-dependent pathways. Our results suggest a
model whereby SV5 replication induces apoptosis in immature DC but fails to provide strong maturation signals, while activation of NFkB-
dependent pathways by exogenous ligands can lead to moDC maturation and override SV5-induced cell death.
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Dendritic cells (DC) are pivotal professional antigen
presenting cells that are capable of recognizing microbial
products and promoting innate and adaptive immune responses
(Banchereau et al., 2000; Reis e Sousa, 2001). Two major
human DC populations have been described: CD11c− plasma-
cytoid (pDC) and CD11c+ conventional DC (cDC). pDC can
respond to virus infection by producing type I interferon (IFN)
which can limit virus growth (Hengel et al., 2005), but are
thought to be relatively poor at antigen presentation (Barchet et
al., 2005). By contrast, CD11c+ cDC are very efficient at
processing and presenting antigen, and can serve as potent⁎ Corresponding author. Fax: +1 336 716 9928.
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nents, immature DC are triggered to undergo a series of cell
signaling events that result in conversion of an immature
phenotype into a mature form that is capable of activating naive
T cell functions such as proliferation, cytokine secretion and
cytolytic activity (Banchereau et al., 2000; Reis e Sousa, 2001).
These DC maturation events include an increased cell surface
expression of costimulatory molecules such as CD40, CD80,
CD86, downregulation of antigen capture receptors and
increased capacity to secrete immunomodulatory cytokines
such as interleukin-12 (IL-12), IL-6, IL-8 and TNF-α
(Banchereau et al., 2000; Reis e Sousa, 2001).
Virus-induced DC maturation can occur through recognition
of components of the incoming virion particle or as newly
synthesized viral components (Biron, 1999; Boehme and
Compton, 2004; Klagge and Schneider-Schaulies, 1999). A
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Toll-like receptor (TLR) pathway (Iwasaki and Medzhitov,
2004; Pasare and Medzhitov, 2004; Takeda and Akira, 2004).
Individual TLRs recognize a specific type of microbial
component and initiate a cascade of intracellular signaling
events that result in activation of the transcription factor NFkB
and induction of host genes associated with antigen presentation
and inflammatory responses. For recognition of RNA viruses,
important TLRs include TLR-3, which recognizes dsRNA
(Alexopoulou et al., 2001) and TLR-7 and TLR-8, which
recognize ssRNA (Diebold et al., 2004; Heil et al., 2004; Lund
et al., 2004). For some RNA viruses such as mouse mammary
tumor virus, measles virus and respiratory syncytial virus
(RSV), viral glycoproteins have been reported to activate TLR-
2 or -4 (reviewed in Boehme and Compton, 2004). Immature
DC can also be activated by alternative mechanisms that do not
depend on TLR signaling (Lopez et al., 2006), but the pathways
for TLR-independent recognition of virus infection are not
completely understood.
Clearance of a viral infection and the subsequent develop-
ment of long-term adaptive immunity depends on appropriate
innate and adaptive responses at the time of infection (Biron,
1999), and DC play a pivotal role in linking these two arms of
immunity (Banchereau et al., 2000; Reis e Sousa, 2001). As
such, many viruses are poor inducers of maturation pathways in
infected immature DC, resulting in limited production of
cytokines and upregulation of costimulatory molecules (Klagge
and Schneider-Schaulies, 1999). Examples of this include
herpes simplex virus, cytomegalovirus (CMV), vaccinia virus,
measles virus, parainfluenza virus type 3, Lassa fever virus,
hantavirus, polio virus and Ebola virus (Baize et al., 2004;
Bosio et al., 2003; Engelmayer et al., 1999; Grosjean et al.,
1997; Moutaftsi et al., 2002; Plotnicky-Gilquin et al., 2001;
Raftery et al., 2002; Schneider-Schaulies et al., 2003; Wahid et
al., 2005). This lack of maturation following infection of
immature DC could result from a virus-induced suppression of
signaling pathways. For example, CMV infection of immature
DC fails to induce maturation, but infected cells are also
refractory to maturation induced by external stimuli (Moutaftsi
et al., 2002). However, many viral infections of immature DC
are highly cytopathic. Thus, in these cases, it is not clear if the
lack of maturation following infection is due to active
suppression of host cell signaling pathways or to a more
general cytopathic effect (CPE) that indirectly limits maturation.
Our work and the work of others have shown that in human
epithelial- and fibroblast-derived cells, the paramyxovirus SV5
is unusual among closely related viruses by being a poor
inducer of host cell death pathways (Choppin, 1964; Lin et al.,
2003; He et al., 2002; Wansley and Parks, 2002; Wansley et
al., 2003). Similar results demonstrating a noncytopathic
phenotype for WT SV5 were found with primary cultures of
human epithelial cells (Wansley et al., 2005). Remarkably, the
outcome of WT SV5 infection of primary cultures of human
myeloid-derived immature DC (moDC) is very different, as
we have recently shown that SV5 establishes a productive
infection of immature moDC that is highly cytopathic with
activation of apoptosis (Arimilli et al., 2006). Thus, host celldeath pathways are differentially activated by WT SV5
infections of epithelial cells (limited CPE) versus immature
moDC (high CPE).
In addition to being highly cytopathic in primary cultures of
human immature DC, we have previously shown that WT SV5
is a poor inducer of CD40, CD80 and CD86 maturation markers
and cytokine secretion (Arimilli et al., 2006). We hypothesized
that the lack of maturation of SV5-infected immature moDC
could result from two nonexlusive mechanisms: a cytopathic
effect that indirectly precludes DC maturation or an active
mechanism for suppression of maturation signaling pathways.
Here we have examined the relationship between SV5-induced
DC death pathways and the activation of DC maturation
pathways. Our results suggest a model whereby the lack of
maturation of SV5-infected DC is not due to apoptosis per se or
to a global inhibition of maturation pathways, but rather a
failure to provide sufficiently strong maturation signals.
Activation of NFkB-dependent pathways by exogenous ligands
can lead to maturation of infected cells and override SV5-
induced cell death without inhibiting virus replication.
Results
A pan-caspase inhibitor reduces apoptosis in SV5-infected
human moDC, but results in limited activation of maturation
markers
Primary cultures of immature monocyte-derived DC (moDC)
were generated by selection of CD14-positive cells from PBMC
followed by culturing for 6 days with recombinant GM-CSF and
IL-4 as detailed previously (Arimilli et al., 2006). Greater than
95% of this immature DC population was CD11c+ (not shown).
To analyze SV5-induced cytopathic effects (CPE) and apopto-
sis, immature moDC were infected with WT recombinant SV5
(rSV5) or rSV5-EGFP, a WT rSV5 engineered to encode EGFP
as an additional gene between the viral HN and L genes as
described previously (He et al., 1997). At 22 hpi, cells were
examined by microscopy for CPE and EGFP expression. As
shown in Fig. 1A, the majority of mock-infected immature
moDC were found as adherent healthy cells with some rounded
cells that were still attached to the dish. By contrast, immature
moDC infected with WT rSV5 showed increased levels of
cellular debris, and many cells were detached from the dish and
floating. Likewise, infections with rSV5-EGFP showed that
nearly all cells were expressing EGFP (EGFP panel, Fig. 1A),
and the CPE was indistinguishable from that seen with WT
rSV5. When analyzed by flow cytometry, a low percentage of
mock-infected immature moDC showed staining with an
antibody specific for cleaved active caspase-3 (Fig. 1B). By
contrast, a much larger percentage of immature moDC infected
with either WT rSV5 or rSV5-EGFP showed high levels of
cleaved caspase-3. The percentage of cells with active caspase-3
staining was reduced when infected cells were cultured with the
pancaspase inhibitor z-VAD-FMK. We have not detected
differences in any properties of WT rSV5 and rSV5-EGFP in
immature DC, including the kinetics of viral gene expression or
appearance of apoptotic markers (see below).
Fig. 1. WT SV5 and rSV5-EGFP are cytopathic in primary cultures of immature moDC. (A) Immature moDC from a representative donor were mock-infected or
infected at an moi of 5 with WT rSV5 or rSV5-EGFP. Phase-contrast and EGFP expression were visualized at 22 hpi. (B) Immature moDC infected with the indicated
viruses were analyzed by flow cytometry at 22 hpi for intracellular levels of activated caspase-3 and cell surface CD11c. z-VAD-FMK was included in one culture of
infected DC at 100 μM. Numbers in the upper quadrant indicate the percent of CD11c+ cells that stained positive for cleaved caspase-3. Representative of three
experiments.
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human immature moDC do not show an increase in surface
expression of maturation markers such as CD40, CD80 or
CD86 (Arimilli et al., 2006). To determine if inhibiting SV5-
induced apoptosis leads to increased surface maturation marker
expression, mock-infected or infected immature moDC were
cultured in the presence of the pancaspase inhibitor z-VAD-
FMK. As shown in Fig. 2, the pancaspase inhibitor reduced
levels of cleaved caspase-3 in SV5-infected immature moDC.
However, the levels of cell surface maturation markers CD40,
CD80 and CD86 were not above that seen for inhibitor-treated
mock-infected cells and were much lower than that seen with
LPS-treated control cells (Figs. 2B–D). Uninfected control DC
that were treated with a TLR-3 agonist gave CD40, and CD86
levels that were 3- to 4-fold over mock-treated cells (see below).
These data indicate that the lack of maturation of SV5-infected
moDC cannot be solely accounted for by the induction of
apoptosis.
Maturation of SV5-infected moDC in response to treatment
with TLR-4 and -6 agonists
Previous results with epithelial and fibroblast cell lines have
shown that SV5 infection induces the loss of STAT1, resulting
in a block in IFN signaling pathways (Didcock et al., 1999b).
This raised the hypothesis that the lack of induction ofmaturation markers following WT rSV5 infection was due to
virus-induced inhibition of maturation pathways. As a first step
in testing this hypothesis, we determined the kinetics of viral
protein expression, STAT1 degradation and appearance of
apoptosis markers. Immature moDC were mock-infected or
infected at high moi with WT rSV5 and cell lysates were
analyzed by western blotting at 0, 6, 12 and 22 hpi. As shown
for a representative donor in Fig. 3A, SV5 P protein was
detected by 6 hpi, and accumulated to higher levels by 12 and
22 hpi. Similarly, STAT1 levels were greatly reduced by 6 hpi
and were at the limit of detection by 22 hpi.
Abundant viral protein expression and STAT1 degradation
occurred before the appearance of apoptotic markers. This is
evident in Fig. 3B, which shows the kinetics of appearance of
cleaved caspase-3 and annexin-V staining for mock-infected
and SV5-infected immature moDC. A large increase in the
percentage of infected cells with elevated active caspase-3 was
apparent between 7 and 13 hpi, and continued to increase out to
24 hpi. There was a modest increase in the percentage of mock-
infected cells with active caspase-3 staining at 24 hpi, but this
was not reproducibly seen with all donors. Very similar kinetics
were seen for the percentage of infected cells with high levels of
surface annexin-V staining (right panel, Fig. 3B).
As shown in the timecourse in Fig. 3C, immature moDC
treated with 200 ng/ml of LPS show elevated levels of cell
surface CD80 and CD86 compared to mock-treated samples
Fig. 2. Pan-caspase inhibitor decreases apoptosis in SV5-infected immature moDC, but results in only low levels of cell surface maturation markers. Immature moDC
were mock-infected or infected at an moi of 5 with WT rSV5 and then treated with or without 100 μM z-VAD-FMK. Levels of intracellular cleaved caspase-3 (A) and
the indicated cell surface maturation markers (B–D) were assayed by flow cytometry at 24 hpi. Cells treated with 200 ng/ml of LPS were used as a positive control.
Results are the average of three experiments from three individual donors (with standard error bars). Results in panels B–D are expressed as a fold change relative to
mock-infected, mock-treated sample set at 1.
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infected cells show either very poor induction (CD86; Fig. 3C)
or decreased levels (CD80; Fig. 3C) of these maturation
markers over time. Taken together, these data indicate that WT
SV5 infection of immature moDC results in a very rapid
reduction of STAT1 that begins prior to 6 hpi and apoptotic
markers begin to increase between 7 and 13 hpi, but maturation
markers do not increase during this timeperiod.
To test the hypothesis that SV5 imposes a block in DC
maturation pathways, SV5-infected immature moDC were
treated with compounds that activate TLR signaling, a known
pathway leading to DC maturation (Iwasaki and Medzhitov,
2004). TLR-2–6 and -8 were chosen for activation, based on the
previously established TLR expression patterns of in vitro-
differentiated human moDC (Iwasaki and Medzhitov, 2004),
and the role for individual TLRs in recognition of viral
components (Boehme and Compton, 2004). Cells were mock-
infected or infected at high moi with WT rSV5. At 7 hpi, cells
were then mock-treated or treated with individual TLR agonists
as detailed in Materials and methods. This timepoint for agonistchallenge was chosen based on the kinetics of appearance of
apoptotic markers in SV5-infected DC shown in Fig. 3, with the
goal of activating signaling pathways before extensive CPE had
occurred. At 22 hpi, cells were then analyzed for surface
maturation markers CD40, CD86, and CD80.
Fig. 4 shows the average mean fluorescence intensity (MFI)
from three experiments with three donors expressed as a fold
increase over that seen with immature moDC that were mock-
infected and mock-treated. In the case of CD40, treatment of
mock-infected cells with each of the individual TLR agonists
gave a ∼2- to 6-fold increase in surface marker expression (Fig.
4A, black bars). The highest levels of CD40 on mock-infected
cells were seen after treatment with the TLR-4 agonist LPS and
TLR-6 agonist FSL1. CD86 responses in TLR agonist-treated
mock-infected cells were similar to that seen for CD40, except
that TLR-2, -3 and -6 responses were approximately equal (Fig.
4B, black bars). For CD80, TLR-4 and -6 agonists induced the
highest responses, which were∼4- to 7-old above mock-treated
cells, while the other TLR responses were much lower (e.g.,
TLR-2) or were not above background levels.
Fig. 3. Timecourse of STAT1 degradation, viral protein expression, apoptotic markers and maturation markers during SV5 infection of immature moDC. (A) Immature
moDC from a representative donor were mock-infected (M lanes) or infected at an moi of 5 with WT rSV5 (S lanes). Cell lysates were prepared at the indicated times
pi, and analyzed by western blotting for STAT1, P protein and actin. (B and C) Timecourse of appearance of apoptotic markers and maturation markers. Immature DC
from a representative donor were mock-infected or infected at an moi of 5 with WT rSV5. At the indicated times pi, cells were analyzed by flow cytometry for
intracellular levels of active caspase-3 and cell surface annexin-V (panel B), or for cell surface CD86 and CD80 (C). In panel C, a sample of mock-infected immature
moDC were treated at time 0 with LPS to serve as a positive control for the timecourse of appearance of DC maturation markers.
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and -8 resulted in only minimal increases in CD40, CD86 or
CD80 surface expression (Fig. 4, gray bars). By contrast,
treatment of infected cells with TLR-4 or -6 agonists resulted in
elevated levels of all three maturation markers, with the
strongest response coming from treatment with the TLR-4
activator LPS. The response of SV5-infected immature moDC
was most clear in the case of CD80, where addition of TLR-4
and TLR-6 agonists gave ∼5.5- and 2.5-fold increases in
surface marker expression compared to the lack of response
following treatment with TLR-2, -3, -5, and -8 agonists. Cellsurface maturation markers on TLR-4 and -6-treated cells were
always lower for infected cells compared to agonist-treated
mock-infected cells, but were always higher than that of
untreated SV5-infected DC.
Taken together, these data indicate that SV5-infected
immature moDC respond to TLR-4 and -6 agonists by
expressing higher levels of cell surface maturation markers
CD40, CD86, and CD80, as well as secretion of prototypic
immunomodulatory cytokines. Thus, the lack of DC maturation
following WT SV5 infection is not the result of a global block in
maturation pathways.
Fig. 5. Apoptotic markers in SV5-infected immature moDC are reduced by
treatment with TLR-4 and -6 agonists. Mock-infected or WT rSV5-infected
immature DC were treated at 7 hpi with the indicated TLR agonists as detailed in
Materials and methods. Cells were analyzed by flow cytometry at 22 hpi for
levels of intracellular cleaved caspase-3 (A) or cell surface annexin-V staining
(B). Results are the mean values (with standard error bars) from three
experiments with three individual donors. *, P values for percent active caspase-
3 and annexin positive cells on TLR-4 agonist-treated SV5-infected cells
compared to untreated infected control cells were 0.007. #, P values for percent
active caspase-3 and annexin positive cells on TLR-6 agonist-treated infected
cells compared to untreated infected control cells were 0.01 and 0.017,
respectively.
Fig. 4. TLR-4 and -6 agonists induced cell surface maturation markers on SV5-
infected immature moDC. Immature moDC were mock-infected or infected at
an moi of 5 with WT rSV5. At 7 hpi, cells were mock-treated or treated with the
indicated TLR agonists as detailed in Materials and methods. Levels of cell
surface CD40 (A), CD86 (B) and CD80 (C) were determined by flow cytometry.
Mean fluorescent intensities from three experiments using three individual
donors (with standard error bars) are expressed as a fold change relative to
mock-infected, mock-treated sample set at 1 (indicated by horizontal line). *, P
values for CD40, CD86 and CD80 on TLR-4 agonist-treated SV5-infected cells
compared to untreated infected control cells were 0.0003, 0.002 and 0.005,
respectively. #, P values for CD40, CD86 and CD80 on TLR-6 agonist-treated
infected cells compared to untreated SV5-infected control cells were 0.002,
0.04, and 0.007, respectively.
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agonists without elimination of virus replication
During our analysis, we observed that SV5-infected
immature moDC showed reduced CPE following treatment
with TLR-4 and -6 agonists (see below). To determine if
treatment with TLR ligands altered SV5-induced apoptosis,
immature moDC were mock-infected or infected with WT SV5
at high moi. At 7 hpi, cells were treated with TLR agonists as
described above, and levels of cleaved caspase-3 and surface
annexin-V staining were determined by flow cytometry at
22 hpi. In the absence of TLR challenge, >50% of WT SV5-
infected immature DC expressed high levels of active caspase-3
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infected cells were positive for surface annexin-V staining (Fig.
5B). There was only a modest change in levels of cleaved
caspase-3 and annexin-V staining with infected cells treated
with agonists for TLR-2, -3, -5, and -8. By sharp contrast, there
was a substantial decrease in the percentage of infected cells
with active caspase-3 staining following treatment with TLR-4
agonist LPS (<10%) or the TLR-6 agonist FSL1 (<20%).
Similarly, the percentage of infected cells staining positive for
Annexin-V was decreased by treatment with TLR-4 and -6
agonists (Fig. 5B), while other TLR ligands had much less of an
effect.
To confirm these results, TLR agonist-treated immature
moDC were analyzed by microscopy. As shown in Fig. 6A, theFig. 6. TLR-4 and -6 agonist treatment of SV5-infected immature moDC does not r
mock-infected or infected with rSV5-EGFP at an moi of 5. At 6 hpi, samples were l
agonist FSL1 (100 ng/ml). Phase contrast pictures and EGFP expression were assa
infected as described for panel A, except that cell lysates were prepared at 0 and 6 hpi
or FSL1 (F lanes). Cell lysates were prepared at 12 and 22 hpi, and levels of SV5 P an
two experiments. (C) At 6 hpi, immature moDC infected with rSV5-EGFP were left un
Values are the average of three experiments using three donors with standard deviatmajority of immature mock-infected and untreated (UT) DC
were found as flat cells with a small percentage of rounded but
attached cells. This contrasts with the large CPE seen following
rSV5-EGFP infection (Fig. 6A), including cell rounding,
detachment from the dish, and increased cellular debris.
Importantly, treatment of infected immature DC with the
TLR-4 agonists LPS or TLR-6 agonist FSL1 resulted in a
decrease in CPE and cellular debris, and a large fraction of cells
were found in an elongated form as well as rounded cells still
attached to the dish (Fig. 6A). Similar morphological changes
were induced by agonist treatment of mock-infected cells.
Immature DC infected with both WT rSV5 or rSV5-EGFP
showed reduced CPE following agonist treatment which was
indistinguishable (not shown).educe virus replication. (A) Immature moDC from a representative donor were
eft untreated (UT) or treated with the TLR-4 agonist LPS (200 ng/ml) or TLR-6
yed at 22 hpi. Representative of three experiments. (B) Immature moDC were
. Parallel samples were then left untreated (U lanes) or treated with LPS (L lanes)
d V proteins or cellular actin were assayed by western blotting. Representative of
treated (UT) or treated with LPS or FSL1. Virus titers were determined at 22 hpi.
ions indicated by bars.
Fig. 7. Enhanced maturation and reduced CPE in SV5-infected moDC treated
with the non-TLR agonist IL-1β. Immature moDC were mock-infected or
infected at high moi with WT rSV5. At 6 hpi, cells were left untreated (UT
samples) or treated with 10 ng/ml IL-1β. Levels of cell surface CD40 (A), CD80
(B) and intracellular cleaved caspase-3 (panel C) were determined by flow
cytometry. Results are the average of mean fluorescent intensities from three
experiments using three individual donors (with standard error bars). CD40 and
CD80 results are expressed as a fold change relative to mock-infected, mock-
treated sample set at 1. *, P values for CD40 and CD80 on IL-1β-treated
infected cells compared to untreated infected control cells were 0.007 and 0.02,
respectively. #, P values for percent active caspase-3 on IL-1β-treated infected
cells compared to untreated infected control cells was 0.05.
151S. Arimilli et al. / Virology 365 (2007) 144–156As shown in Fig. 6A, LPS or FSL1 treatment of SV5-EGFP-
infected DC did not reduce EGFP expression, suggesting that
TLR activation of maturation pathways did not abort viral
replication. To directly test this, rSV5-EGFP-infected immature
moDC were treated with LPS or FSL1 at 6 hpi, and the
accumulation of viral proteins over time was analyzed by
western blotting. As shown in Fig. 6B, viral P and V protein
levels in infected immature moDC increased between 6 and
12 hpi, but importantly, the increased levels of P and V did not
differ significantly between control untreated cells and cells
treated with LPS or FSL1 (Fig. 6B, U lane versus L and F
lanes). By 22 hpi, the levels of P and V proteins were slightly
higher in cells treated with the TLR-4 and TLR-6 agonists. In
addition, treatment of WT rSV5 infected immature moDC with
LPS or FSL1 did not decrease virus yield compared to untreated
cells (Fig 6C). Taken together, these data indicate that treatment
of SV5-infected immature moDC with TLR-4 or TLR-6 ligands
leads to enhanced DC maturation and reduced apoptosis and
CPE, but does not reduce virus replication.
Reduced CPE and enhanced maturation following treatment
of SV5-infected immature moDC with the non-TLR activator
IL-1β
The above data indicate that activation of TLR-4 and -6
pathways in SV5-infected immature moDC leads to decreased
apoptosis and maturation. Since TLR activation leads to
induction of NFkB activity (Pasare and Medzhitov, 2004), we
hypothesized that other non-TLR ligands that similarly activate
NFkB could have a similar effect on infected immature DC. To
test this hypothesis, mock-infected or WT rSV5-infected
immature moDC were treated at 6 hpi with or without IL-1β
(10 ng/ml). At 24 hpi, DC maturation and apoptotic markers
were analyzed by flow cytometry. As shown in Fig. 7A and B,
IL-1β treatment increased surface expression of CD40 and
CD80 on mock-infected as well as SV5-infected cells. The
levels of maturation marker expression induced by IL-1β were
lower than that seen after LPS treatment, but were similar to that
induced by the TLR-6 agonist FSL1. Importantly, IL-1β
treatment of infected immature DC also reduced the percentage
of cells with high levels of activated caspase-3 (Fig. 7C) and
overall CPE in the culture (not shown). Together, these data
indicate that the ability of exogenous ligands to increase
maturation and decrease CPE and apoptosis of SV5-infected
immature DC is not limited to responses initiated by the TLR
agonists LPS and FSL1.
TLR-4 mediated maturation and reduced apoptosis of
SV5-infected immature moDC is blocked by NFkB inhibitors
The above data demonstrate an inverse relationship between
the maturation of SV5-infected immature moDC by exogenous
stimuli and reduced levels of CPE and apoptosis. To test the
hypothesis that maturation and reduced apoptosis were linked
through common pathways, infected immature moDC were
treated with inhibitors of NFkB, a transcription factor that is
essential for TLR-mediated induction of CD40 and CD80
Fig. 8. TLR-4 mediated maturation and reduced apoptosis of SV5-infected immature moDC are blocked by NFkB inhibitors. Immature moDC were mock-infected or
infected at high moi with WT rSV5 and left untreated (UT; black bars) or cultured in the presence of 10 μM PDTC (P, white bars). At 6 hpi, 200 ng/ml LPS was added
to samples lacking PDTC (L, gray bars) or samples treated with PDTC (P+L, striped bars). At 22 hpi, samples were analyzed as detailed in the legend to Fig. 7. *, P
values for CD40 and CD80 on P+L treated infected cells compared to L treated infected control cells were 0.006 and 0.018, respectively. #, P values for percent active
caspase-3 and annexin positive cells on P+L treated infected cells compared to L treated infected control cells were 0.1 and 0.034, respectively.
152 S. Arimilli et al. / Virology 365 (2007) 144–156(Ardeshna et al., 2000). Immature DC were mock-infected or
infected at high moi with WT rSV5 and cells were then cultured
with or without the NFkB inhibitor PDTC (Schreck et al.,
1992). At 6 hpi, samples were left unchallenged or challenged
with LPS to induce maturation.
As shown in Fig. 8, addition of PDTC to both mock-infected
and WT rSV5-infected cells had little effect on the levels of
maturation markers CD40 and CD80 (compare UT and P bars,
panels A and B), as well as the percentage of infected cells with
high apoptotic markers (compare UT and P bars, panels C and
D). LPS treatment enhanced maturation marker expression and
decreased apoptotic markers on both mock-infected and
infected immature moDC, as shown in prior figures. Most
importantly, in the presence of the NFkB inhibitor, LPS
treatment did not increase maturation of infected or control
immature moDC, and the percentage of infected cells with high
apoptotic markers was similar to that of untreated (UT) or
PDTC-treated cultures (P). Very similar results were found
using the TLR-6 agonist FSL1 and the non-TLR ligand IL-1βas inducers of maturation and Bay11943 as an alternative NFkB
inhibitor (not shown). These data indicate that NFkB is a
common factor playing a key role in the ability of exogenous
ligands to enhanced maturation and override apoptosis in SV5-
infected immature moDC.
Discussion
The paramyxovirus SV5 is unusual among this family of
viruses since it is a poor inducer of apoptosis in human
epithelial- and fibroblast-derived cells (Choppin, 1964; Lin et
al., 2003; He et al., 2002; Wansley and Parks, 2002; Wansley et
al., 2003). Remarkably, the ability of SV5 to limit the activation
of host cell death pathways is not evident in primary cultures of
human moDC (Arimilli et al., 2006), since WT SV5 infection
results in high CPE and activation of apoptosis. In the case of
the paramyxoviruses respiratory syncytial virus (RSV) and
human parainfluenza virus type 3 (HPIV-3), infection of human
immature DC is highly cytopathic, but infected cells still
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Plata et al., 2006; Plotnicky-Gilquin et al., 2001). This contrasts
with the cytopathic SV5 infection of immature DC that does not
result in maturation. The goal of the work described here was to
determine the relationship between activation of cell death and
the lack of maturation in SV5-infected immature moDC. We
have shown that under conditions of reduced CPE and
apoptosis, infected immature DC did not show a substantial
increase in cell surface maturation markers. This result
demonstrates that the lack of maturation is not the result of
apoptosis per se, and suggests that SV5 infection either blocks
maturation or does not produce viral components that are
sufficient for inducing maturation.
Virus-induced DC maturation can be viewed in part as an
anti-viral response to infection, since many of the signaling
pathways and cellular sensors are shared between these two host
cell responses (Lopez et al., 2003, 2006). Thus, viruses that
specifically target innate immune responses may also target DC
maturation pathways. A number of negative strand RNAviruses
have been shown to impose a block in the ability of DC to
mature. For example, influenza virus attenuates maturation of
immature moDC through the action of the NS1 protein
(Fernandez-Sesma et al., 2006). RSV infection of human
moDC and pDC can result in a block in dsRNA-mediated
activation of maturation pathways and IFN production
(Guerrero-Plata et al., 2006; Schlender et al., 2005). In a
mouse transgenic system using immature bone marrow-derived
DC, measles virus infection results in a block in the IL-12
response to TLR-4 agonists by a mechanism that is independent
of the viral V or C proteins (Hahm et al., 2007).
Based on these examples and the known effect of SV5 on
suppressing antiviral signaling pathways in epithelial and
fibroblast cells (Didcock et al., 1999a, 1999b; Poole et al.,
2002), we tested the hypothesis that SV5 also imposed a global
block in maturation pathways. Infected immature moDC
showed a rapid loss of STAT1, consistent with SV5 imposing
a block in IFN signaling pathways (Didcock et al., 1999a), and
this occurred before detectable CPE and the appearance of
apoptotic markers (Fig. 2). However, at this time pi, SV5-
infected immature moDC were still capable of responding
strongly to TLR-4 and TLR-6 agonists by showing upregulation
of maturation markers CD40, CD80 and CD86. Thus, SV5
selectively targets the inhibition of some innate response
pathways in moDC (e.g., IFN induction and signaling), but
other innate pathways remain functional. The ability of SV5-
infected immature moDC to respond to exogenous ligands was
not limited to agonists 4 and 6, since IL-1β also enhanced
moDC maturation. This is consistent with previous results with
epithelial cells showing that while SV5 is a poor inducer of
cytokines, infection does not result in a block in the ability of
infected cells to respond to exogenous cytokines such as TNF-α
or IL-1β (Young and Parks, 2003). Together, these data
demonstrate that the lack of maturation of SV5-infected
immature moDC is not due to a global inhibition of signaling
pathways initiated by exogenous ligands.
When TLR agonists were tested, maturation of SV5-infected
moDC was clearly apparent with TLR-4 and -6 ligands,indicating that SV5 did not impose a global block on DC
maturation. The lack of response to TLR-2, -3, -5 and -8 agonists
could reflect specific blocks in these individual signaling
pathways, or a nonspecific CPE that precludes responses to
treatment. The ability of infected cells to specifically respond to
TLR-4 and -6 ligands raises the question of what unique features
allow these signaling pathways to override SV5-induced
apoptosis and activate DC maturation. TLR-6 functions as an
oligomer with TLR-2, but the TLR-6/2 complex recognizes
distinct microbial products and activates cells through different
pathways than TLR-2 homo-oligomers (Iwasaki andMedzhitov,
2004). Importantly, TLR-4 and TLR-6/2 signaling pathways
have been shown to differ from other TLR pathways (Takeda
and Akira, 2004) by their dependence on MyD88 in conjunction
with a cytoplasmic adaptor protein called TIRAP (TIR domain-
containing adaptor protein) or Mal (MyD88-adaptor-like). Thus,
the ability of moDC to signal through TIRAP-dependent
pathways may be responsible for the striking ability of TLR-4
and TLR-6/2 agonists to reverse apoptosis and promote
maturation of SV5-infected DC compared to other TLR
agonists.
Why does SV5 fail to induce maturation of human immature
moDC, despite growing to high titers and producing large
quantities of viral gene products? Our results are similar to those
reported for Lassa virus (Baize et al., 2006), where infection of
immature moDC is highly productive but DC do not express
maturation markers unless they are challenged with exogenous
TLR agonists. Baize et al. (2006) proposed that infected DC do
not mature because Lassa virus replication does not produce
high levels of key viral components that trigger intracellular
signaling pathways. DC maturation through intracellular path-
ways may occur by dsRNA-activated cellular proteins such as
PKR, MDA-5 or RIG-I (Lopez et al., 2006), and may require a
threshold level of dsRNA to activate signaling pathways. It has
recently been shown using transfected cell lines that the
paramyxovirus V protein can inhibit MDA-5 but not RIG-I
pathways (Childs et al., 2007). RIG-I has been shown to play an
important role in IFN and proinflammatory cytokine responses
in paramyxovirus-infected murine cDC (Kato et al., 2005),
raising the question of why the high levels of SV5 replication in
immature moDC do not activate RIG-I-dependent maturation
pathways. Virus preparations that are rich in defective
interfering (DI) particles are potent inducers of DC maturation
(Yount et al., 2006), which presumably reflects the large
amounts of dsRNA produced by copy-back DI particles during
replication. Thus, SV5 may limit TLR-independent DC
maturation by limiting the production of dsRNA or other
intracellular signals. Taken together, our data are consistent with
the proposal of Baize et al. (2006) that the lack of maturation of
infected immature moDC is not due to a global block in
signaling, but rather, results from virus replication that fails to
produce significant levels or types of key components such as
dsRNA that triggers intracellular maturation pathways (Lopez
et al., 2006).
Treatment of SV5-infected immature moDC with exogenous
ligands revealed an inverse relationship between the induction
of maturation and decreased apoptosis. It is well established that
154 S. Arimilli et al. / Virology 365 (2007) 144–156in DC the upregulation of maturation markers (Ardeshna et al.,
2000) and proinflammatory cytokine synthesis are dependent
on NFkB activation. NFkB can also play important roles in
expression of either proapoptotic or antiapoptotic genes,
depending on the host cell type and the type of stimulation
(Dutta et al., 2006). In this regard, immature moDC have been
shown to be dependent on NFkB for both maturation and
survival following LPS treatment (Ardeshna et al., 2000).
Consistent with this, results with NFkB inhibitors showed that,
in SV5-infected immature moDC, the ability of TLR-4 and
TLR-6 agonists to both decrease apoptosis and to activate
maturation is blocked by NFkB inhibitors. Thus, NFkB may
serve as a common transcription factor for two distinct
pathways that lead to maturation of SV5-infected DC as well
as overriding apoptosis signals by inducing prosurvival genes
(Ardeshna et al., 2000).
Our results suggest a model whereby SV5 infection of
immature moDC activates apoptosis through pathways that are
independent of NFkB, and this is consistent with our finding that
NFkB inhibitors do not prevent SV5-induced apoptosis (Fig. 8).
In our model, DC maturation pathways and NFkB function are
not activated during virus replication because SV5 does not
encode the prototypic TLR ligands described for other viruses
(Boehme and Compton, 2004) and the production of intracel-
lular signals such as dsRNA is limited. Addition of exogenous
ligands to SV5-infected DC activates NFkB signaling, which
leads to induction of genes encoding maturation markers and
cytokines, as well as expression of pro-survival gene products
which override virus-induced apoptosis.
Due to their critical role in activation of naive T cells, there is
intense interest in developing methods to promote maturation
and antigen presentation in virus-infected DC. In the case of
viruses that are highly cytopathic to DC, cell killing could
contribute to poor activation of T cell responses and adaptive
immunity as proposed previously for a number of viruses (e.g.,
Muller et al., 2004; Wahid et al., 2005). It may be possible to
develop vaccine strategies such that TLR-4 or -6/2 pathways are
activated in virus-infected DC, which could lead to decreased
DC death and increased capacity of infected DC to initiate
antiviral immune responses.
Materials and methods
Cells, viruses and reagents
Immature peripheral blood mononuclear cell (PBMC)-
derived human DC were prepared as described previously
(Arimilli et al., 2006). Briefly, PBMC were isolated from
randomly selected healthy donors by standard density gradient
centrifugation on Ficoll–Hypaque. CD14+ cells were isolated
by positive selection using CD14 microbeads. Typically,
the purity of monocytes isolated by this procedure was
≥95%. Enriched CD14+ cells (106 cells/ml in 5 ml) were cul-
tured for 6 days in culture medium containing 10 ng/ml human
interleukin-4 and 10 ng/ml human granulocyte-macrophage
colony-stimulating factor. On day 3, half of the medium was
replaced with fresh medium supplemented with cytokines to theabove final concentrations. Greater than 95% of this immature
DC population was CD11c+ (not shown).
Recombinant WT SV5 (WT rSV5) was recovered as
described previously (He et al., 1997) from cDNA plasmid
kindly provided by Robert Lamb and Biao He (Northwestern
University). The rSV5-GFP infectious clone kindly provided by
Robert Lamb and Biao He was used as starting material to
generate an rSV5 that encoded the gene for enhanced green
fluorescence protein (EGFP) between HN and L (details
available on request). The EGFP open reading frame also
contained an 18 residue C-terminal extension encoding the
immunodominant p60 epitope from Lysteria monocytogenes
(single letter amino acid code: ALSVKYGVSVQDIMSWNN).
Viruses were grown in MDBK cells, and purified as described
previously (Arimilli et al., 2006). SV5 infections were carried
out as described previously (Arimilli et al., 2006). In experi-
ments with TLR agonists, DC were infected and then treated at
the indicated time post infection with the following agonists
according to the manufacturer's recommendations (Invivogen;
San Diego, CA): heat killed Listeria monocytogenes for TLR-2
(108 cells per ml); Poly(I:C) for TLR-3 (2.5 μg/ml); E. coli K12
LPS for TLR-4 (200 ng/ml); S. typhimurium flagellin for TLR-5
(200 ng/ml); Pam2CGDPKHPKSF (FSL1), a synthetic lipopro-
tein from Mycoplasma salivarium, for TLR-6 (100 ng/ml);
Imiquimod R837 for TLR-7 (1 μg/ml); ssRNA40 for TLR-8
(1 μg/ml). Cells were analyzed for maturation markers or
cytokine secretion at 22–24 hpi. Pyrrolidine dithiocarbamate
(PDTC) and z-VAD-FMK were from Sigma and Promega,
respectively.
Cytokine production and cell surface staining
Cytokines IL-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α,
were quantified by an inflammatory response cytometric bead
array assay (BD Pharmingen, San Diego, CA). For detection of
surface markers, DCs were stained with the following
conjugated monoclonal antibodies according to the manufac-
turer's recommendations, CD11c (B-ly6), CD14 (M5E2),
CD40 (5C3), CD80 (L307.4) and CD86 (FUN-1) all from BD
Pharmingen (San Diego, CA). Samples were analyzed on a
FACScan instrument using Cell Quest software (Becton
Dickinson, San Diego, CA). A Student's t test was used to
determine significance between samples.
Western blotting, microscopy and cytometric analyses of
apoptotic cells
Levels of viral and cellular protein were analyzed by western
blotting as described previously (Arimilli et al., 2006).
Equivalent amounts of protein were analyzed by western
blotting using polyclonal rabbit antibodies specific for SV5 P
(Parks et al., 2001), a monoclonal antibody V5 specific for an
epitope in theN-terminal region of the SV5 P andV (Invitrogen),
rabbit polyclonal antibodies against cellular STAT1 protein
(clone 554, Santa Cruz Biotechnology) or a monoclonal
antibody specific for actin (Sigma) followed byHRP-conjugated
secondary antibodies and ECL.
155S. Arimilli et al. / Virology 365 (2007) 144–156Microscopy was carried out as described previously (Arimilli
et al., 2006) using a Nikon Eclipse fluorescence microscope
using a 20× lens. Images were captured using a QImaging digital
camera and processed using QCapture software. Exposure times
were manually set to be constant between samples.
Apoptosis was measured as described previously (Arimilli et
al., 2006) by intracellular staining for active caspase-3 using
PE-conjugated polyclonal anti-caspase-3 antibody (Pharmin-
gen, San Diego, CA) along with CD11c-APC, or by measuring
cell surface staining with PE-conjugated annexin-V. Samples
were analyzed by flow cytometry. A Student's t test was used to
determine significance between samples.
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